Pharma Deals Review, Vol 2006, No 71 (2006)

Font Size:  Small  Medium  Large

Almirall Signs Deal with Forest for COPD Therapy

Business Review Editor

Abstract


Almirall Prodesfarma entered into an agreement with Forest Laboratories Holdings to develop, market and distribute Almirall’s muscarinic antagonist LAS34273 for chronic obstructive pulmonary disease, asthma and bronchitis in US.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.